不同方案玻璃体腔注射康柏西普治疗SNPDR的临床研究  

Clinical study of different regimens of intravitreal injection of Conbercept in the treatment of SNPDR

作　　者：杜秋霞 孔瑞芹[2] Du Qiu-xia;Kong Rui-qin(Department of Ophthalmology,Luoyang Boai Eye Hospital,Luoyang 471000,Henan,China;Ophthalmology Department,the SecondAffiliated Hospital of Henan University of Science and Technology,Luoyang 741000,Henan,China)

机构地区：[1]洛阳博爱眼科医院眼科,河南洛阳471000 [2]河南科技大学第二附属医院眼科,河南洛阳741000

出　　处：《四川生理科学杂志》2024年第3期545-547,共3页Sichuan Journal of Physiological Sciences

摘　　要：目的:分析不同方案玻璃体腔注射康柏西普治疗重度非增殖性糖尿病视网膜病(severe Non-proliferative diabetic retinopathy,SNPDR)的效果.方法:选择2021年3月至2022年3月就诊于本院的110例(110眼)SNPDR患者,随机分为两组.3+PRN组(55例55眼),连续3次每月玻璃体腔注射康柏西普后改用按需治疗方案;5+PRN组(55例55眼),连续5次每月玻璃体腔注射康柏西普后改用按需治疗方案,治疗后随访6 m.对比两组治疗前、治疗后3 m、治疗后6 m的最佳矫正视力(Best Corrected Visual Acuity,BCVA)、黄斑中心凹厚度(Central Foveal Thickness,CFT)、微动脉瘤(Microaneurysm,MA)、黄斑区深层血管密度(Deepretinal Capillary of vessel,DCPVD).结果:5+PRN组注射次数多于3+PRN组(P<0.05);治疗后6 m,5+PRN组BCVA高于3+PRN组,CFT、MA低于3+PRN组(P<0.05);两组治疗后3、6 m的DCPVD相比,差异无统计学意义.结论:3+PRN、5+PRN玻璃体腔注射康柏西普均可有效治疗SNPDR,但5+PRN治疗方案可更好改善患者6 m后的视力与眼底指标.Objective:To analyze the clinical effects of different regimens of intravitreal injection of Conbercept in the treatment of severe non-proliferative diabetic retinopathy(SNPDR).Methods:110 patients(110 eyes)with SNPDR from March 2021 to March 2022 were randomly divided into two groups.In 3+PRN group(55 cases,55 eyes),the patients were treated with on-demand therapy after three consecutive monthly injections of Conbercept into vitreous cavity.In the 5+PRN group(55 cases,55 eyes),the patients were treated with on-demand treatment after 5 consecutive monthly injections of Conbercept into vitreous cavity,and were followed up for 6 months.The best corrected visual acuity(BCVA),macular fovea thickness(CFT),microaneurysm(MA)and macular deep vascular density(DCPVD)were compared between the two groups before treatment,3 months after treatment and 6 months after treatment.Results:The number of injections in 5+PRN group was more than that in 3+PRN group(P<0.05).Six months after treatment,BCVA in 5+PRN group was higher than that in 3+PRN group,while CFT and MA in 5+PRN group were lower than those in 3+PRN group(P<0.05).There was no significant difference in DCPVD between the two groups at 3 and 6 months after treatment.Conclusion:The intravitreal injection of 3+PRN or 5+PRN with compatriot can both effectively treat SNPDR,but the 5+PRN regimen is more conducive to improving the patient's vision and fundus indicators after six months.

关 键 词：重度非增殖性糖尿病视网膜病变 玻璃体腔注射 康柏西普 

分 类 号：R774.1[医药卫生—眼科]